Janux Therapeutics, Inc.
JANX
$23.64
$0.632.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | 20.42% | |||
| Gross Profit | -- | -20.42% | |||
| SG&A Expenses | 6.22% | 19.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.29% | 20.24% | |||
| Operating Income | -29.29% | -20.24% | |||
| Income Before Tax | -44.03% | -16.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.03% | -16.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.03% | -16.28% | |||
| EBIT | -29.29% | -20.24% | |||
| EBITDA | -29.67% | -20.58% | |||
| EPS Basic | -43.80% | -6.94% | |||
| Normalized Basic EPS | -43.73% | -6.97% | |||
| EPS Diluted | -43.80% | -6.94% | |||
| Normalized Diluted EPS | -43.73% | -6.97% | |||
| Average Basic Shares Outstanding | 0.18% | 8.73% | |||
| Average Diluted Shares Outstanding | 0.18% | 8.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||